The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test ...

Tempus AI agreed to acquire Personalis for $1.5 billion, but the stock fell on dilution concerns. Here is why analysts still back the AI diagnostics play.

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus AI has agreed to buy the rest of genomics company Personalis in a deal that expands the technology company's capabilities in minimal residual disease. Tempus, which already owns more than 12% ...

Tempus AI, a company that brings artificial intelligence to diagnostics, is growing its capabilities in oncology through a $1.5 billion deal to buy Personalis and its commercialized test for detecting ...

Tempus AI acquires Personalis to expand its oncology testing portfolio and address a $20B+ MRD detection market with 10% penetration. Personalis brings innovative cancer detection technology, robust ...

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. Tempus, which is putting a total enterprise value of $1.5 billion on ...

Tempus AI is strengthening its position in minimal residual disease (MDR) testing with the proposed $1.5 billion acquisition of Personalis. The deal is expected to close in late 2026 or early 2027.

Tempus AI has agreed to acquire the cancer genomics company Personalis in a deal valued at about $1.5 billion, the companies announced July 20. The acquisition builds on a partnership the two ...

Tempus AI, a technology platform leveraging AI to advance precision medicine and patient care, recently announced its plans to acquire Personalis, a company specializing in early detection of small ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Personalis shareholders will ...